Mesa Laboratories, Inc. announced that it has entered into separate, privately negotiated purchase agreements with a limited number of holders of its outstanding 2025 Notes at the gross proceeds of $71,250,000 on April 5, 2024. The principal amount of the transaction is $75,000,000. The notes bear 1.375% Convertible Notes due 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
116 USD | -0.91% | +0.47% | +10.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.76% | 626M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+3.43% | 26.53B | |
+13.67% | 25.02B | |
-0.32% | 24.96B |
- Stock Market
- Equities
- MLAB Stock
- News Mesa Laboratories, Inc.
- Mesa Laboratories, Inc. announced that it expects to receive $71.25 million in funding